Background: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype, with 150,000 new cases yearly. Roughly 40% of patients who receive rituximab in addition to vincristine, cyclophosphamide, doxorubicin, and prednisone treatment have primary refractory disease or recurrence. Although the Ann Arbor stage could determine DLBCL prognosis, new biomarkers are needed to stratify patient pro…